Werewolf Therapeutics (NASDAQ:HOWL) Downgraded to “Neutral” Rating by Wedbush

Wedbush lowered shares of Werewolf Therapeutics (NASDAQ:HOWL) from an outperform rating to a neutral rating in a research report report published on Friday morning, MarketBeat Ratings reports. They currently have $1.00 target price on the stock.

HOWL has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. JMP Securities decreased their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. HC Wainwright cut their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Bank of America reduced their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Stock Up 6.2%

NASDAQ HOWL opened at $0.69 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 52 week low of $0.56 and a 52 week high of $2.38. The firm has a market capitalization of $33.34 million, a price-to-earnings ratio of -0.42 and a beta of 0.74. The company has a fifty day moving average of $1.18 and a two-hundred day moving average of $1.31.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Luke Evnin sold 23,640 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80. Following the transaction, the director owned 2,866,488 shares in the company, valued at approximately $3,067,142.16. This trade represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the completion of the sale, the insider owned 4,784,111 shares of the company’s stock, valued at $4,640,587.67. The trade was a 1.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 5,337,021 shares of company stock worth $6,108,970. 23.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the business. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics in the second quarter worth approximately $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter worth $71,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the first quarter valued at about $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics in the second quarter valued at about $92,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.